The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following ...

At the heart of many modern scientific discoveries lies technology — the tools that allow researchers to see, measure and ...

Summit Therapeutics said its closely tracked antibody, the first lung cancer drug to beat Merck’s Keytruda in a head-to-head ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...